Jefferies analyst Akash Tewari maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $100.00. The company’s shares closed today at $90.00.
According to TipRanks, Tewari is a 5-star analyst with an average return of 21.5% and a 59.15% success rate. Tewari covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Eli Lilly & Co, and Neurocrine.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $115.63 average price target, representing a 28.48% upside. In a report released today, UBS also maintained a Hold rating on the stock with a $110.00 price target.
See today’s best-performing stocks on TipRanks >>
BNTX market cap is currently $22.11B and has a P/E ratio of 8.08.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE (BNTX) Company Description:
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Read More on BNTX:
- BioNTech Expects Continued Growth into 2024
- Options Volatility and Implied Earnings Moves Today, March 20, 2024
- BioNTech Welcomes New Chief Commercial Officer
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
- Novavax (NASDAQ:NVAX) Remains Highly Speculative, Post-Pandemic
